Biogen Inc. - Common Stock (BIIB)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — May 3, 2026Investment Snapshot
- Trading 37% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 5/9 — moderate financial health
- ROE of 14.3% — below-average profitability
Biogen Inc. - Common Stock (BIIB) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $27.6 billion . Key value metrics: P/E ratio 16.6, P/B ratio 1.54, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Biogen Inc. - Common Stock — Fundamental Analysis Summary
Biogen Inc. - Common Stock (BIIB) is currently trading 37% above its Graham Number of $136.99, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a reasonable trailing P/E ratio of 16.6x.
On financial health, BIIB shows a moderate Piotroski F-Score of 5/9, and modest return on equity of 14.3% (sector average: -20.6%), and manageable leverage with a debt-to-equity ratio of 0.58.
StockPik's composite Value Score for BIIB is 71/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
BIIB reports a high gross margin of 74.5% (sector average: 40.1%) and a strong operating margin of 25.9%.
BIIB shows revenue growing at 2% year-over-year, with earnings declining at 21%.